| Oct 16 |
Unicycive Therapeutics to Participate in a Fireside Chat at the 2024 Maxim Healthcare Virtual Summit on October 17, 2024
|
| Oct 16 |
Results of Phase I trial shed positive light on UNI-494 for acute kidney injury
|
| Oct 9 |
Unicycive Therapeutics Successfully Completes UNI-494 Phase 1 Study in Healthy Volunteers
|
| Sep 20 |
Life Sciences Virtual Investor Forum Presentations Now Available for Online Viewing
|
| Sep 16 |
Life Sciences Virtual Investor Forum Agenda Announced for September 19th
|
| Sep 16 |
Unicycive Therapeutics to Present at the Virtual Life Sciences Investor Forum on September 19, 2024
|
| Sep 5 |
Unicycive Therapeutics to Present at the H.C. Wainwright 26th Annual Global Investment Conference
|
| Aug 21 |
Companies Like Unicycive Therapeutics (NASDAQ:UNCY) Are In A Position To Invest In Growth
|
| Aug 14 |
Unicycive Therapeutics GAAP EPS of -$0.29
|
| Aug 14 |
Unicycive Announces Second Quarter 2024 Financial Results and Provides Business Update
|
